Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 3, 2012 (14 years ago)

Moexipril HCl Tablets 7.5mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Paddock Laboratories, LLC are recalling one lot (2012028142) of Moexipril HCl Tablets 7.5mg (expiration 1/2014) because of a non-conformity dissolution failure result found during routine stability testing at the 6 month test interval.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Moexipril HCl Tablets 7.5mg, 100 tabs, Rx Only, Paddock Laboratories, Inc., Minneapolis, MN 55427, NDC 0574-0110-01 ,

Affected NDC 0574-0110-01

Compare with the code on your package — it is the most precise check available.

Drug: Moexipril

Recalling firm
Paddock Laboratories, LLC
NDC code
0574-0110-01
Origin
MN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-007-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Moexipril recalls

See all

Other recalls by Paddock Laboratories, LLC

All 2012 recalls
Class II · Moderate risk

Evamist (estradiol transdermal spray)

Defective Delivery System: Potential that cracks in the vial neck near the crimp may result in product evaporation and/or leaking and the inability to properly dispense product.

Terminated Packaging defect Paddock Laboratories, LLC. D-0608-2018
Class II · Moderate risk

Perrigo

Presence of Particulate Matter Perrigo is recalling seven lots of Clindamycin Palmitate Hydrochloride for Oral Solution 75mg/5ml.

Terminated Particulate / foreign matter Paddock Laboratories, LLC NDC 0574-0129-01 D-1168-2014

Other dissolution failure recalls from 2012

All dissolution failure recalls
Class II · Moderate risk

Taztia XT

Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).

Terminated Dissolution failure Watson Pharmaceuticals NDC 62037-700-90 D-145-2013